Perceptive Advisors LLC Tcr2 Therapeutics Inc. Transaction History

Perceptive Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $259,555 - $564,317	-30,753 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $4.64 Million - $6.98 Million	-282,547 Reduced 90.18%	30,753 $505,000
Q1 2021 May 17, 2021	SELL	$20.38 - $34.07 $1.77 Million - $2.95 Million	-86,700 Reduced 21.68%	313,300 $6.92 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $5.24 Million - $8.28 Million	400,000 New	400,000 $8.13 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.